REPONEX PHARMACEUTICALS A/S: Financial statements 2016
CVR: 30082346
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK 241,832 and a net result of DKK -331,569 compared with DKK -933,677 the year before. Equity in the 2016 report amounted to DKK 5,230,192. The solvency ratio was 65.9%.
- Gross Profit
- DKK 241,832
- Profit/Loss
- DKK -331,569
- Equity
- DKK 5,230,192
- Total Assets
- DKK 7,939,896
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | 242 t. | -332 t. | 5.2 mio. | - |
| 2015 | - | -1.2 mio. | -934 t. | 536 t. | - |
| 2014 | 1 | -34 t. | -683 t. | 1.5 mio. | - |
| 2013 | - | - | 150 t. | 230 t. | - |
| 2012 | - | - | -18 t. | 80 t. | - |
Official annual report
Find more companies like REPONEX PHARMACEUTICALS A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
As of June 25, 2016, Erik Lennard Vitting Skovbjerg has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2015. Gross profit came to DKK -1,182,333, and the net result was DKK -933,677.
As of June 21, 2016, Troels Peter Troelsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 21, 2016, Erik Lennard Vitting Skovbjerg has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 20, 2016, Troels Peter Troelsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of April 19, 2016, Torsten Bjørn is registered as director of REPONEX PHARMACEUTICALS A/S.
As of April 19, 2016, Henrik Lasse Lindblad has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.